<DOC>
	<DOC>NCT03086382</DOC>
	<brief_summary>The purpose of this study is to demonstrate bioequivalence between the LCM tablet and syrup after single oral dosing in healthy Chinese male subjects.</brief_summary>
	<brief_title>A Study to Investigate the Bioequivalence of Lacosamide Tablet (200mg) and Syrup (10mg/ml) in Healthy Chinese Male Subjects</brief_title>
	<detailed_description />
	<mesh_term>Lacosamide</mesh_term>
	<criteria>Subject is a Chinese male between 18 and 40 years of age Subject has no clinically significant cardiovascular, renal, gastrointestinal, hepatic, metabolic, endocrine, neurological, or psychiatric abnormalities and is in general good health Subject confirms that during the study and for a period of 3 months after the final dose of study drug, when having sexual intercourse with a woman of childbearing potential, an acceptable birth control method will be used Clinically significant out of range values for hematology and clinical chemistry variables abnormality in physical examination or vital signs ECG finding Any clinical conditions that in the opinion of the investigator would make the subject unsuitable for the study</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Lacosamide</keyword>
	<keyword>Syrup</keyword>
	<keyword>Bioequivalence</keyword>
	<keyword>Tablet</keyword>
</DOC>